表紙
市場調查報告書

類鴉片物質使用障礙 (OUD):流行病學的預測 (到2028年)

Opioid Use Disorder - Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 952795
出版日期 內容資訊 英文 34 Pages
訂單完成後即時交付
價格
類鴉片物質使用障礙 (OUD):流行病學的預測 (到2028年) Opioid Use Disorder - Epidemiology Forecast to 2028
出版日期: 2020年07月30日內容資訊: 英文 34 Pages
簡介

全球主要8個國家的類鴉片物質使用障礙 (OUD)的患病人數,2018年達到年度320萬5478人。今後預計以負0.77%的年複合成長率持續減少,2028年達到295萬7666人。在分析觀察對象國家中美國患病人數最大量 (200萬1944人),丹麥最少 (2萬3528人)。

本報告提供全球主要8個國家 (美國、加拿大、澳洲、德國、比利時、奧地利、瑞士、丹麥) 的類鴉片物質使用障礙 (OUD)的發病情形與今後預測相關分析,疾病的特徵和目前患病者的發病情形,今後10年的患病人數 (總數/已受診患者數)的趨勢預測,調查男女、各症狀、各年齡詳細趨勢等。

目錄

第1章 目錄

第2章 類鴉片物質使用障礙 (OUD):概要

第3章 流行病學

  • 病的背景情況
  • 危險因素與並存症
  • 全球過去趨勢
  • 預測手法
    • 使用的資訊來源
    • 預測的前提條件與方法
    • 預測的前提條件與方法:OUD的患病者總數 (過去12個月)
    • 預測的前提條件與方法:OUD的已受診患病人數 (過去12個月)
    • 預測的前提條件與方法:OUD的患病者總數/已受診患病人數 (過去12個月)
    • 沒使用的資訊來源
  • 類鴉片物質使用障礙 (OUD):流行病學的預測 (2018∼2028年)
    • OUD的患病者總數 (過去12個月)
    • OUD的患病人數:各年齡 (過去12個月)
    • OUD的患病人數:男女 (過去12個月)
    • OUD的患病人數:各重症度 (過去12個月)
    • OUD的已受診患病人數 (過去12個月)
    • OUD的已受診患病人數:各年齡 (過去12個月)
    • OUD的已受診患病人數:男女 (過去12個月)
    • OUD的已受診患病人數:各重症度 (過去12個月)
  • 討論
    • 流行病學預測的考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

目錄
Product Code: GDHCER246-20

Opioid use disorder (OUD) is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a problematic pattern of opioid use leading to clinically significant impairment or distress. Symptoms of OUD include strong desire for opioids, inability to control or reduce use, continued use despite interference in major obligations or social functioning, use of larger amounts over time, development of tolerance, spending a great deal of time to obtain and use opioids, and withdrawal symptoms that occur after stopping or reducing use such as negative mood, nausea or vomiting, muscle aches, diarrhea, fever, and insomnia (American Psychiatric Association, 2013).

GlobalData epidemiologists utilized historical data obtained from peer-reviewed articles and reports to build the forecast for the 12-month total and 12-month diagnosed prevalent cases of OUD in the 8MM. GlobalData epidemiologists applied the 12-month total and 12-month diagnosed prevalence of OUD drawn from the above sources to each country's population to calculate the12-month total and 12-month diagnosed prevalent cases OUD.

The following data describes the epidemiology forecast of OUD. In the 8MM, GlobalData epidemiologists forecast a decrease in the 12-month total prevalent cases of OUD from 3,205,478 cases in 2018 to 2,957,666 cases in 2028, at a negative Annual Growth Rate (AGR) of 0.77%. In 2028, the US will have the highest number of 12-month total prevalent cases of OUD in the 8MM, with 2,001,944 12-month total prevalent cases, whereas Denmark will have the fewest number of total prevalent cases with 23,528 cases. In the 8MM, the 12-month diagnosed prevalent cases of OUD are expected to decrease from 1,708,553 cases in 2018 to 1,576,482 cases in 2028, at a negative AGR of 0.77%.

Scope

  • The Opioid Use Disorder Epidemiology Report provides an overview of the risk factors and global trends of Opioid Use Disorder Epidemiology (OUD) in the eight major markets (8MM: US, Canada, Australia, Germany, Belgium, Austria, Switzerland, and Denmark).
  • The report includes a 10-year epidemiology forecast for the 12-month total prevalent cases (including both diagnosed and undiagnosed cases) and 12-month diagnosed prevalent cases of OUD. The 12-month total prevalent cases and 12-month diagnosed prevalent cases of OUD are further segmented by sex, and age (18 years and older). Additionally, the 12-month total prevalent cases and 12-month diagnosed prevalent cases of OUD are segmented by severity (mild, moderate, and severe).
  • The OUD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The OUD Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global OUD market.
  • Quantify patient populations in the global OUD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for OUD therapeutics in each of the markets covered.
  • Understand magnitude of OUD population by major comorbidities.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Opioid Use Disorder: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources Used
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of OUD
    • 3.4.4 Forecast Assumptions and Methods: 12-Month Diagnosed Prevalent Cases of OUD
    • 3.4.5 Forecast Assumptions and Methods: 12-Month Total and Diagnosed Prevalent Cases of OUD by Severity
    • 3.4.6 Sources Not Used
  • 3.5 Epidemiological Forecast for OUD (2018-2028)
    • 3.5.1 12-Month Total Prevalent Cases of OUD
    • 3.5.2 Age-Specific 12-month Total Prevalent Cases of OUD
    • 3.5.3 Sex-Specific 12-Month Total Prevalent Cases of OUD
    • 3.5.4 12-Month Total Prevalent Cases of OUD by Severity
    • 3.5.5 12-Month Diagnosed Prevalent Cases of OUD
    • 3.5.6 Age-Specific 12-Month Diagnosed Prevalent Cases of OUD
    • 3.5.7 Sex-Specific 12-Month Diagnosed Prevalent Cases of OUD
    • 3.5.8 12-month Diagnosed Prevalent Cases of OUD by Severity
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of Analysis
    • 3.6.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for OUD

List of Figures

  • Figure 1: 8MM, 12-Month Total Prevalent Cases of OUD, Both Sexes, N, Ages ≥18 Years, 2018 and 2028
  • Figure 2: 8MM, 12-Month Diagnosed Prevalent Cases of OUD, Both Sexes, N, Ages ≥18 Years, 2018 and 2028
  • Figure 3: 8MM, 12-Month Total Prevalence of OUD, Men and Women, %, Ages ≥18 Years, 2018
  • Figure 4: 8MM, 12-Month Diagnosed Prevalence of OUD, Men and Women, %, Ages ≥18 Years, 2018
  • Figure 5: 8MM, Sources Used and Not Used to Forecast the 12-Month Total and 12-Month Diagnosed Prevalent Cases of OUD
  • Figure 6: 8MM, Sources Used to Forecast the Severity of 12-Month Total Prevalent Cases of OUD
  • Figure 7: 8MM, Sources Used to Forecast the Severity of 12-Month Diagnosed Prevalent Cases of OUD
  • Figure 8: 8MM, 12-Month Total Prevalent Cases of OUD, Both Sexes, Ages ≥18 Years, N, 2018
  • Figure 9: 8MM, 12-Month Total Prevalent Cases of OUD by Age, N, Both Sexes, 2018
  • Figure 10: 8MM, 12-Month Total Prevalent Cases of OUD by Sex, N, Ages ≥18 Years, 2018
  • Figure 11: 8MM 12-Month Total Prevalent Cases of OUD by Severity, N, Ages ≥18 Years, 2018
  • Figure 12: 8MM, 12-Month Diagnosed Prevalent Cases of OUD, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 13: 8MM, 12-Month Diagnosed Prevalent Cases of OUD by Age, N, Both Sexes, 2018
  • Figure 14: 8MM, 12-Month Diagnosed Prevalent Cases of OUD by Sex, N, Ages ≥18 Years, 2018
  • Figure 15: 8MM, 12-Month Diagnosed Prevalent Cases of OUD by Severity, N, Ages ≥18 Years, 2018